GlassScriptPhysician profile
Wonsick Choe
NPI 1689070690
$1,188.92
in general payments reported to CMS, 2019-2025
19 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Nuclear Medicine provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2022: $130 · 2023: $338 · 2024: $214 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $179.94 | 2019 | |
| Novo Nordisk INC | $165.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $152.31 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $124.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $81.37 | 2024-2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $76.57 | 2022 | |
| Pfizer INC. | $63.77 | 2023-2024 | |
| Viiv Healthcare Company | $59.93 | 2025 | Apretude |
| Almatica Pharma LLC | $40.70 | 2023 | Loreev Xr, Gralise |
| Glaxosmithkline, LLC. | $39.54 | 2022-2024 | Shingrix, Bexsero |
| Sumitomo Pharma America, INC. | $36.38 | 2023 | Myfembree |
| Sanofi Pasteur INC. | $31.46 | 2023 | |
| Merck Sharp & Dohme LLC | $27.01 | 2019-2023 | Proquad, Vaxneuvance, Vaxelis |
| Phathom Pharmaceuticals, INC. | $23.77 | 2025 | Voquezna |
| Biomarin Pharmaceutical INC. | $19.22 | 2025 | Voxzogo 1.2mg |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.58 | 2019 | |
| Alk-Abello, INC | $17.08 | 2023 | Grastek, Odactra |
| Bayer Healthcare Pharmaceuticals INC. | $16.08 | 2022 | |
| Lilly USA, LLC | $14.52 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonsick Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.